Everest Secures Exclusive Rights to Sumecigrel (Vicagrel) Across Multiple Asia-Pacific Markets
registration, and commercialization in multiple countries and regions across the Asia-Pacific, including Southeast Asia, South Korea, Australia, as well as Hong Kong (China), Macau (China), and Taiwan (China).
Vicagrel has been granted exclusive rights for clinical development, registration, and commercialization in multiple countries and regions across the Asia-Pacific, including Southeast Asia, South Korea, Australia, as well as Hong Kong (China), Macau (China), and Taiwan (China), under an exclusive licensing agreement announced on June 9 between Everest Medicines and Vcare PharmaTech.
Vicagrel is a Category 1 novel antithrombotic drug independently developed by Vcare PharmaTech and is a next-generation oral P2Y12 receptor antagonist. According to reports, the design concept of Vicagrel aims to address the “clopidogrel resistance” black box warning. It optimizes the metabolic pathway of clopidogrel while retaining the same active metabolite discovery pathway, in order to achieve a more balanced control of the “double-edged sword” between efficacy benefits of antiplatelet therapy and bleeding risk.
Buy Sumecigre online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
